(NASDAQ: KZIA) Kazia Therapeutics's forecast annual revenue growth rate of 125.98% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.72%.
Kazia Therapeutics's revenue in 2026 is $1,346,546.On average, 7 Wall Street analysts forecast KZIA's revenue for 2027 to be $405,851,167, with the lowest KZIA revenue forecast at $0, and the highest KZIA revenue forecast at $1,725,904,701. On average, 7 Wall Street analysts forecast KZIA's revenue for 2028 to be $18,863,089,803, with the lowest KZIA revenue forecast at $0, and the highest KZIA revenue forecast at $83,319,537,290.
In 2029, KZIA is forecast to generate $105,838,484,341 in revenue, with the lowest revenue forecast at $2,133,337,238 and the highest revenue forecast at $215,621,893,713.